Surmodics today announced the successful first clinical uses of the Sublime radial access 0.018 RX percutaneous transluminal angioplasty (PTA) dilatation catheter.
Ankur Lodha, perfomed the first procedures with the device at Cardiovascular Institute of the South’s office-based catheterisation lab in Lafayette, USA. Subsequently, Imraan Ansaarie, utilised the Sublime radial access 0.018 RX PTA dilatation catheter in cases at Advanced Endovascular Institute of St Augustine in St Augustine, USA. The device is the latest addition to the Sublime radial access platform, joining the Sublime radial access guide sheath and the Sublime radial access 0.014 RX PTA dilatation catheter.
“Sublime radial access RX PTA dilatation catheters will allow physicians to treat the most distal blockages in the foot with just radial access. This will help us perform more complex interventions via this approach which was not possible prior,” said Lodha.
“This Sublime radial access 0.018 RX PTA dilatation catheter is a great addition to the current devices available for minimal arterial access lower extremity intervention procedures,” added Ansaarie.
The Sublime radial access 0.018 RX PTA dilatation catheter, which received US Food and Drug Administration (FDA) 510(k) clearance in June 2021, allows above- or below-the-knee access through a transradial approach by providing the longest working length (220cm) on the market. Outer balloon diameters range from 2–6mm, allowing for treatment in larger vessels, with balloon lengths between 20mm and 220mm. With a proprietary shaft construction incorporating a flexible distal segment, a supportive proximal segment, and a mid-shaft that transitions from supportive to flexible, the Sublime 0.018 RX PTA dilatation catheter is designed to provide improved pushability, trackability and crossability in an RX platform.
The Sublime radial access 0.018 RX PTA dilatation catheter is indicated for PTA dilation of peripheral vasculature stenosis in the iliac, femoral, iliofemoral, popliteal, infrapopliteal, and renal arteries, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulas. The device is contraindicated for use in the coronary arteries and the neurovasculature.